Anaplastic Oligodendroglioma (AO) Completed Phase 1 Trials for Sirolimus (DB00877)

Also known as: Anaplastic Oligodendroglioma / Anaplastic Oligodendrogliomas / Malignant oligodendroglioma / Oligodendroglioma, anaplastic (morphologic abnormality) / Oligodendroglioma malignant

IndicationStatusPhase
DBCOND0052374 (Anaplastic Oligodendroglioma (AO))Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01522820Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsTreatment